HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and gastric cancer (GC) In addition, it develops Tazemetostat, an inhibitors of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients.
